logo
logo

ProMIS Neurosciences secures $9.2 million through private placement financing to support Alzheimer's drug development.

Jul 22, 2025•13 days ago

Amount Raised

$9.2 Million

TorontoBiotechnology

Description

ProMIS Neurosciences has successfully raised $9.2 million through a strategic financing initiative. This includes $2.4 million from a private placement and $6.8 million from existing warrant exercises. The funds will advance the clinical development of PMN310, the company's lead therapeutic candidate for Alzheimer's disease. The private placement is expected to close on July 24, 2025.

Company Information

Company

ProMIS Neurosciences

Location

1920 Yonge St., Suite 200

Toronto, Ontario, Canada

About

ProMIS Neurosciences is a clinical-stage biotechnology company committed to the discovery and development of therapeutic antibodies selective for toxic oligomers associated with the development and progression of neurodegenerative and other misfolded protein diseases. The Company’s proprietary target discovery engine, EpiSelect™, predicts novel targets known as Disease Specific Epitopes (DSEs) on the molecular surface of misfolded proteins that cause neurodegenerative and other misfolded protein diseases, including Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS), frontotemporal dementia (FTD), multiple system atrophy (MSA), and Parkinson’s Disease (PD).

Related People